3PBIOVIAN Launches AAVion Platform to Streamline Gene Therapy Manufacturing

• 3PBIOVIAN has launched the AAVion Platform, a fully integrated AAV manufacturing solution covering vector design to aseptic fill and finish.

• The company also offers a standalone Plasmid Platform delivering research to GMP-grade plasmid DNA for various therapeutic applications.

3PBIOVIAN, a CDMO partner in biopharmaceutical manufacturing, has announced the launch of its AAVion Platform—an end-to-end adeno-associated virus (AAV) manufacturing solution aimed at accelerating gene therapy development. The platform is now available to biotech and pharmaceutical companies globally.

The AAVion Platform consolidates key steps of AAV manufacturing into a single, integrated process. This includes vector design, in-house plasmid production, cell banking, upstream and downstream processing, quality control, and aseptic fill and finish. It is built around a proprietary HEK293 cell line and supports multiple AAV serotypes, from small-scale lab work to clinical production in single-use bioreactors.

According to the company, the in-house purification process allows for high titers and purities across serotypes with minimal optimisation. Aseptic fill and finish, clinical labelling, and direct delivery to trial sites are all managed under one roof, supporting faster time-to-clinic and simplifying the contract manufacturing process.

In parallel, 3PBIOVIAN has made its Plasmid DNA (pDNA) Platform available as a standalone service. The platform supplies research-grade, HQ, and GMP-grade plasmids produced entirely in-house. These plasmids are intended not only for AAV production but also for mRNA, cell therapies, and vaccines.

“AAVion is the result of focused development and cross-functional expertise in gene therapy manufacturing,” said Pirkko Kortteinen, COO of 3PBIOVIAN. “With our high-yield HEK293 cell line and integrated capabilities, we are able to deliver scalable AAV production tailored to our clients’ serotype and clinical needs.”

Both platform offerings reflect 3PBIOVIAN’s strategy to serve as a comprehensive CDMO partner, particularly for small and mid-sized biotechs seeking end-to-end support in complex gene therapy workflows.